That's the strange thing here, the drug performed well but the placebo too. How is that possible? Were the placebo people even suffering and how valid are those responses?
Maybe big pharma looks at the drug and ignores placebo opposite to the ASX market which put more focus on the placebo than the actual drug performance.
The placebo clouded the great performance, according to the webinar. Let's see how those react who are much more knowledgeable the people like me.
GLTA
Ann: ACW XanaCIDD phase 2a trial topline results, page-61
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
-0.045(59.2%) |
Mkt cap ! $84.06M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.7¢ | 2.5¢ | $3.093M | 99.90M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 2638151 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 1623309 | 5 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| ACW (ASX) Chart |